TY  - JOUR
A1  - Elgaz, Sümmeyye
A1  - Bönig, Halvard-Björn
A1  - Bader, Peter
T1  - Mesenchymal stromal cells for osteonecrosis
T2  - Journal of translational medicine
N2  - Osteonecrosis (ON) is an acquired debilitating skeletal disorder, which is caused by a multitude of traumatic and non-traumatic etiological factors. Vascular damage, mechanical stress and increased intraosseous pressure have been discussed as contributors to ON. The optimal treatment of ON remains to be determined, since the current gold standard, core decompression, is insufficiently effective. Specific properties of mesenchymal stromal cells (MSCs) provide the rationale for their assessment in advanced stages of ON: Osteoinductive potential has been demonstrated and MSC preparations of suitable quality for use as medicinal products have been developed. Here we review the scant information on the use of allogeneic or autologous MSCs in advanced ON as well as potentially supportive data from pre-clinical studies with autologous bone marrow mononuclear cells (auto BM-MNCs), which have been studied quite extensively and the presumed therapeutic effect of which was attributed to the rare MSCs contained in these cell products. Outcomes in clinical trials with MSCs and auto-BM-MNCs remain preliminary and non-definitive, at best promising, with respect to their pharmacological effect. Clearly, though, the application of any of these cell therapies was technically feasible and safe in that it was associated with low complication rates. The heterogeneity of cell type and source, study protocols, cell manufacturing, cell properties, cell doses and surgical techniques might contribute to inconsistent results.
KW  - Mesenchymal stromal cells (MSC)
KW  - Osteonecrosis
KW  - Cell-based therapies
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/55883
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-558836
SN  - 1479-5876
VL  - 18
IS  - Article number: 399
PB  - BioMed Central
CY  - London
ER  -